Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant protein corresponding to a region, which spans the tyrosine kinase catalytic domain and part of the C-terminus of the NPM-ALK transcript|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Neat|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 4 publications below|
MA1-90059 detects ALK-80 from human samples.
MA1-90059 has been successfully used in immunohistochemistry (paraffin tissue) applications. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10mM citrate buffer, p.H. 6.0 prior to immunostaining.
The MA1-90059 immunogen is: Recombinant protein corresponding to a region, which spans the tyrosine kinase catalytic domain and part of the C-terminus of the NPM-ALK transcript
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
MA1-90059 was used in immunohistochemistry to study the prognostic value of the immunohistochemical expression of ALK in patients with neuroblastoma or ganglioblastoma
|Duijkers FA,Gaal J,Meijerink JP,Admiraal P,Pieters R,de Krijger RR,van Noesel MM||The American journal of pathology (180:1223)||2012|
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
MA1-90059 was used in immunohistochemistry to investigate the role of ALK overexpression in B-cell lymphoma/leukemia progression
|Giuriato S,Foisseau M,Dejean E,Felsher DW,Al Saati T,Demur C,Ragab A,Kruczynski A,Schiff C,Delsol G,Meggetto F||Blood (115:4061)||2010|
Diagnostic and differential diagnostic criteria of lymphoid neoplasms in bone marrow trephine biopsies: a study of 87 cases.
MA1-90059 was used in immunohistochemistry to investigate the diagnosis of lymphoid neoplasmas through bone marrow trephine biopsies
|Horváth E,Mezei T,Pávai Z,Turcu M,Demian S,Tóth E,Chira L,Jung I||Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (50:399)||2009|
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
MA1-90059 was used in immunohistochemistry to investigate the usefulness of a specific cancer model for the analysis of ALK-dependent therapy
|Giuriato S,Faumont N,Bousquet E,Foisseau M,Bibonne A,Moreau M,Al Saati T,Felsher DW,Delsol G,Meggetto F||Cancer biology & therapy (6:1318)||2007|
anaplastic lymphoma kinase; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3; TFG/ALK
ALK; CD246; NBLST3